DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Below 50-Day Moving Average – Time to Sell?

DBV Technologies S.A. (NASDAQ:DBVT) shares passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $18.77 and traded as low as $15.69. DBV Technologies shares last traded at $16.11, with a volume of 376,501 shares trading hands.

Analyst Upgrades and Downgrades

DBVT has been the subject of a number of research reports. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Guggenheim reaffirmed a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a report on Monday, May 4th. Finally, Citizens Jmp upped their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Stock Performance

The stock has a 50-day moving average of $18.77 and a two-hundred day moving average of $19.84. The company has a market cap of $953.87 million, a P/E ratio of -3.61 and a beta of -0.99.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million. As a group, sell-side analysts forecast that DBV Technologies S.A. will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

A number of large investors have recently added to or reduced their stakes in the business. Allworth Financial LP bought a new stake in DBV Technologies in the fourth quarter worth $32,000. Royal Bank of Canada purchased a new stake in DBV Technologies during the fourth quarter valued at about $34,000. GAMMA Investing LLC grew its stake in shares of DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after buying an additional 744 shares during the last quarter. Truvestments Capital LLC grew its stake in shares of DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares during the last quarter. Finally, Persistent Asset Partners Ltd purchased a new position in shares of DBV Technologies in the fourth quarter worth about $115,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.